New techniques to improve classical corneal collagen cross-linking treatment.

Na Li, Xiujun Peng, Zhengjun Fan, Yu Xia, Tengfei Wu

Journal: Chinese medical journal 2015;127(8):1558-65

PMID: 24762606

Abstract

OBJECTIVE

The aim of this review is to comprehensively and unbiasedly summarize the improvements in the techniques for classical corneal collagen cross-linking (CXL) by covering the reasons for this improvement, measure, and effect to approach the future direction of the CXL.

DATA SOURCES

All articles used in this review were mainly retrieved from the PubMed database.

STUDY SELECTION

Original articles and reviews were selected if they were related to the improvement in the technique of classical CXL. Data were mainly extracted from 94 articles, which are listed in the reference section of this review.

RESULTS

This innovative research involves every step such as instrument preparation, epithelial management, riboflavin instillation, and UVA irradiation. These clinical and experimental results seem promising.

CONCLUSIONS

CXL treatment is the only recent promising method for preventing the progress of keratoconus. The limitations and potential complications that accompany classical CXL such as corneal thickness limitations, ultraviolet-A (UVA) light injury, and the impact of de-epithelialization encourage people to research new improvements in techniques. While this research needs to be further investigated, we hope our review can help related researchers and patients.

Address: Department of Ophthalmology, Navy General Hospital of Chinese People's Liberation Army, Beijing 100048, China.; Department of Ophthalmology, Navy General Hospital of Chinese People's Liberation Army, Beijing 100048, China. Email: [email protected].

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.